Table 1. Clinical characteristics and responses of L-CTCL patients.

Characteristics	Patients (n=18)
Age - Years old
Median	67.0
Range	54.0 – 79.0
Gender - no. of patients (%)
Female	5 (27.8%)
Male	13 (72.2%)
Stage - no. of patients (%)
III	2 (11.1%)
IV	16 (88.9%)
Modified skin-weighted assessment tool (mSWAT)
≤ 5.0	1(5.5%)
39.0– 80.0	10 (55.6%)
≥ 80.0	7 (38.9%)
Blood involvement *
B1: low blood tumor burden	4 (22.2%)
B2: high blood tumor burden	14 (77.8%)
TCR vβ - no. of patients (%)
Positive	16 (88.9%)
Negative	2 (11.1%)
ECP - no. of cycles**
Median	9.5
Range	6 - 13
Combination immunotherapy - no. of patients (%)
ECP alone	6 (33.3%)
+ Bexarotene	5 (27.8%)
+ IFN-α	2 (11.1%)
+ Bexarotene and IFN-α	5 (27.8%)
Response - no. of patients (%)
Partial response (PR)	8 (44.4%)
Minor response (MR)	4 (22.2%)
Stable disease (SD)	3 (16.7%)
Progressive disease (PD)	3 (16.7%)

^*: circulating CD4⁺CD26^- or CD4⁺CD7^- T-cells;

^**: excluding Patient#8 who had L-CTCL plus GVHD